scispace - formally typeset
X

Xin Ku

Researcher at Shanghai Jiao Tong University

Publications -  25
Citations -  690

Xin Ku is an academic researcher from Shanghai Jiao Tong University. The author has contributed to research in topics: Proteomics & Medicine. The author has an hindex of 8, co-authored 20 publications receiving 559 citations. Previous affiliations of Xin Ku include Chinese Academy of Sciences & Technische Universität München.

Papers
More filters
Journal ArticleDOI

A Series of α-Heterocyclic Carboxaldehyde Thiosemicarbazones Inhibit Topoisomerase IIα Catalytic Activity

TL;DR: Results about the mechanisms involved in the anticancer activities of thiosemicarbazones will aid in the rational design of novel topoisomerase II-targeted drugs and will provide insights into the discovery and development of novel cancer therapeutics based on the dual activity to chelate iron and to inhibit the catalytic activity of topoisomersase IIalpha.
Journal ArticleDOI

ChemMapper: a versatile web server for exploring pharmacology and chemical structure association based on molecular 3D similarity method

TL;DR: This paper presents ChemMapper, an online platform to predict polypharmacology effect and mode of action for small molecules based on 3D similarity computation, which is designed to provide versatile services in a variety of chemogenomics, drug repurposing, polyph pharmacology, novel bioactive compounds identification and scaffold hopping studies.
Journal ArticleDOI

Efficient iron/copper cocatalyzed S-arylations of thiols with aryl halides.

TL;DR: The versatility, air-stability, operational simplicity, and operational simplicity of this protocol, in addition to the higher yields and shorter reaction time it provides, highlight the potential of using this method in large scale library synthesis involving carbon-heteroatom formation.
Journal ArticleDOI

Discovery of Pteridin-7(8H)-one-Based Irreversible Inhibitors Targeting the Epidermal Growth Factor Receptor (EGFR) Kinase T790M/L858R Mutant

TL;DR: The in vivo antitumor efficacy study demonstrated that compound 3x significantly inhibited tumor growth and induced tumor stasis in an EGFR-T790M/L858R-driven human nonsmall-cell lung cancer xenograft mouse model.